Trial Profile
An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Mocetinostat (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Proof of concept; Therapeutic Use
- 26 May 2023 Status changed from active, no longer recruiting to discontinued.
- 19 Sep 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 19 Sep 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.